Which has higher valuation & earnings, ENOV or LIVN?

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.28B 0.66 -$1.18B -$19.88 N/A LivaNova $1.39B 3.28 -$242.47M $1.95 42.55

Is ENOV or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% LivaNova 7.48% 16.48% 7.59%

Does the media refer more to ENOV or LIVN?

In the previous week, Enovis had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Enovis and 2 mentions for LivaNova. LivaNova's average media sentiment score of 1.52 beat Enovis' score of 0.86 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, NVST or ENOV?

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.81B 1.52 $47M $0.41 63.97 Enovis $2.28B 0.66 -$1.18B -$19.88 N/A

Is NVST or ENOV more profitable?

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Envista 2.41% 7.11% 3.91% Enovis -49.92% 10.32% 4.57%

Does the media refer more to NVST or ENOV?

In the previous week, Envista and Envista both had 6 articles in the media. Enovis' average media sentiment score of 0.86 beat Envista's score of 0.65 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ENOV or MMED?

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.28B 0.66 -$1.18B -$19.88 N/A MiniMed Group $3.10B 1.46 -$190.97M -$0.68 N/A

Is ENOV or MMED more profitable?

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% MiniMed Group N/A N/A N/A

Does the media favor ENOV or MMED?

In the previous week, Enovis had 2 more articles in the media than MiniMed Group. MarketBeat recorded 6 mentions for Enovis and 4 mentions for MiniMed Group. Enovis' average media sentiment score of 0.86 beat MiniMed Group's score of 0.73 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENOV or IRTC?

In the previous week, Enovis had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Enovis and 3 mentions for iRhythm Technologies. Enovis' average media sentiment score of 0.86 beat iRhythm Technologies' score of 0.62 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, WRBY or ENOV?

Warby Parker has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $890.57M 3.30 $1.64M $0.02 1,373.45 Enovis $2.28B 0.66 -$1.18B -$19.88 N/A

Is WRBY or ENOV more profitable?

Warby Parker has a net margin of 0.15% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% Enovis -49.92% 10.32% 4.57%

Does the media refer more to WRBY or ENOV?

In the previous week, Enovis had 2 more articles in the media than Warby Parker. MarketBeat recorded 6 mentions for Enovis and 4 mentions for Warby Parker. Enovis' average media sentiment score of 0.86 beat Warby Parker's score of 0.41 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enovis (ENOV) Competitors

$26.28 +0.53 (+2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$26.74 +0.45 (+1.73%)

As of 07:26 PM Eastern

Compare

ENOV vs. LIVN, NVST, MMED, IRTC, and WRBY

Should you buy Enovis stock or one of its competitors? MarketBeat compares Enovis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enovis include LivaNova (LIVN), Envista (NVST), MiniMed Group (MMED), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does Enovis compare to LivaNova?

Enovis (NYSE:ENOV) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

98.4% of Enovis shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
LivaNova	7.48%	16.48%	7.59%

Enovis has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Enovis currently has a consensus price target of $41.71, suggesting a potential upside of 58.73%. LivaNova has a consensus price target of $80.75, suggesting a potential downside of 2.69%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

LivaNova has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.28B	0.66	-$1.18B	-$19.88	N/A
LivaNova	$1.39B	3.28	-$242.47M	$1.95	42.55

In the previous week, Enovis had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Enovis and 2 mentions for LivaNova. LivaNova's average media sentiment score of 1.52 beat Enovis' score of 0.86 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Enovis beats LivaNova on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to Envista?

Envista (NYSE:NVST) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

98.4% of Enovis shares are owned by institutional investors. 1.0% of Envista shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Envista has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Enovis has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

In the previous week, Envista and Envista both had 6 articles in the media. Enovis' average media sentiment score of 0.86 beat Envista's score of 0.65 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.81B	1.52	$47M	$0.41	63.97
Enovis	$2.28B	0.66	-$1.18B	-$19.88	N/A

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Enovis	-49.92%	10.32%	4.57%

Envista presently has a consensus target price of $28.54, indicating a potential upside of 8.81%. Enovis has a consensus target price of $41.71, indicating a potential upside of 58.73%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Enovis beats Envista on 10 of the 16 factors compared between the two stocks.

How does Enovis compare to MiniMed Group?

Enovis (NYSE:ENOV) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.28B	0.66	-$1.18B	-$19.88	N/A
MiniMed Group	$3.10B	1.46	-$190.97M	-$0.68	N/A

Enovis currently has a consensus target price of $41.71, indicating a potential upside of 58.73%. MiniMed Group has a consensus target price of $21.33, indicating a potential upside of 32.51%. Given Enovis' higher probable upside, research analysts plainly believe Enovis is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
MiniMed Group	N/A	N/A	N/A

In the previous week, Enovis had 2 more articles in the media than MiniMed Group. MarketBeat recorded 6 mentions for Enovis and 4 mentions for MiniMed Group. Enovis' average media sentiment score of 0.86 beat MiniMed Group's score of 0.73 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.4% of Enovis shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Enovis beats MiniMed Group on 9 of the 16 factors compared between the two stocks.

How does Enovis compare to iRhythm Technologies?

Enovis (NYSE:ENOV) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

98.4% of Enovis shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enovis currently has a consensus price target of $41.71, suggesting a potential upside of 58.73%. iRhythm Technologies has a consensus price target of $187.38, suggesting a potential upside of 57.89%. Given Enovis' higher probable upside, equities research analysts plainly believe Enovis is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRhythm Technologies has lower revenue, but higher earnings than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.28B	0.66	-$1.18B	-$19.88	N/A
iRhythm Technologies	$747.14M	5.22	-$44.55M	-$0.86	N/A

In the previous week, Enovis had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Enovis and 3 mentions for iRhythm Technologies. Enovis' average media sentiment score of 0.86 beat iRhythm Technologies' score of 0.62 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a net margin of -3.53% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Enovis has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Summary

Enovis beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does Enovis compare to Warby Parker?

Warby Parker (NYSE:WRBY) and Enovis (NYSE:ENOV) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Warby Parker presently has a consensus target price of $29.82, suggesting a potential upside of 8.55%. Enovis has a consensus target price of $41.71, suggesting a potential upside of 58.73%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

Warby Parker has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$890.57M	3.30	$1.64M	$0.02	1,373.45
Enovis	$2.28B	0.66	-$1.18B	-$19.88	N/A

Warby Parker has a net margin of 0.15% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
Enovis	-49.92%	10.32%	4.57%

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 98.4% of Enovis shares are held by institutional investors. 16.8% of Warby Parker shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Warby Parker has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Enovis has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

In the previous week, Enovis had 2 more articles in the media than Warby Parker. MarketBeat recorded 6 mentions for Enovis and 4 mentions for Warby Parker. Enovis' average media sentiment score of 0.86 beat Warby Parker's score of 0.41 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enovis beats Warby Parker on 9 of the 17 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	MEDICAL INFO SYS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.51B	$1.84B	$6.83B	$23.40B
Dividend Yield	N/A	N/A	2.68%	4.03%
P/E Ratio	-1.32	77.24	27.15	31.08
Price / Sales	0.66	28.74	524.22	154.92
Price / Cash	0.96	27.39	29.22	18.64
Price / Book	1.01	5.62	10.75	4.77
Net Income	-$1.18B	-$54.76M	$3.58B	$1.06B
7 Day Performance	1.54%	-3.56%	-2.10%	-0.56%
1 Month Performance	21.12%	5.30%	3.32%	-0.11%
1 Year Performance	-22.77%	-1.36%	28.17%	16.64%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	3.945 of 5 stars	$26.28 +2.1%	$41.71 +58.7%	-24.1%	$1.48B	$2.25B	7.62	7,802
LIVN LivaNova	2.1408 of 5 stars	$84.03 +0.5%	$80.75 -3.9%	+86.2%	$4.59B	$1.39B	43.09	3,300	Positive News
NVST Envista	2.4356 of 5 stars	$27.50 -0.5%	$28.67 +4.2%	+28.5%	$4.50B	$2.72B	67.07	12,000
MMED MiniMed Group	2.6866 of 5 stars	$15.29 -1.9%	$21.33 +39.5%	N/A	$4.29B	$3.10B	N/A	8,000
IRTC iRhythm Technologies	3.7995 of 5 stars	$126.03 -0.4%	$187.38 +48.7%	-14.6%	$4.16B	$747.14M	N/A	2,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors